WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and ...
Anifrolumab-fnia, an IFNAR1-blocking monoclonal antibody, is now authorized for weekly subcutaneous self-administration in adult SLE alongside corticosteroids, antimalarials, and/or immunosuppressants ...
In a new study, researchers examined four randomized controlled trials of belimumab (Benlysta®) to gain a better understanding of systemic lupus erythematosus (SLE) active disease progression with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results